News Related to Unresectable Hepatocellular Carcinoma

Related coverage linked through entity extraction aliases.

Cancer Pipeline Reports Show 45+ CSCC, 70+ Liver Cancer, and Multiple HCC Therapies in Development

Mar 20, 2026

DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.

Nivolumab-Ipilimumab Combination Shows Clinical Gains but Cost-Effectiveness Concerns in HCC

Feb 28, 2026

Nivolumab plus ipilimumab demonstrates survival benefits in unresectable hepatocellular carcinoma but exceeds US cost-effectiveness thresholds at current pricing, with extended dosing intervals or price reductions needed for economic viability.